Morerecent evidence pointed out the prevalent role of HDAC6 inthe beneficial effect of HDAC inhibition especially with respect tothe inflammatory phenotype in CF, thus supporting the evaluation ofHDAC6-selective inhibitors in this context. The gene discussed is HDAC9; the disease is cystic fibrosis.